Finance

Lists
LH:NYSE
Labcorp Holdings Inc
$366.57
+0.90%
(+3.27) 1D
$366.57
0.00% (0.00)
After hours
Closed: Nov 6, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LH...
Open
$357.25
High
$369.06
Low
$355.63
Mkt. cap
29.77B
Avg. vol.
741.31K
Volume
610.11K
Dividend
0.79%
Quarterly dividend
$0.72
Ex-dividend date
May 29, 2026
P/E ratio
30.06
52-wk high
$371.00
52-wk low
$244.52
EPS
$12.19
Beta
0.87
Shares outstanding
81.20M
No. of employees
71K
Open
$357.25
High
$369.06
Low
$355.63
Mkt. cap
29.77B
Avg. vol.
741.31K
Volume
610.11K
Dividend
0.79%
Quarterly dividend
$0.72
Ex-dividend date
May 29, 2026
P/E ratio
30.06
52-wk high
$371.00
52-wk low
$244.52
EPS
$12.19
Beta
0.87
Shares outstanding
81.20M
No. of employees
71K
News stories
From web sources and news partners
Profile
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Wikipedia
About Labcorp Holdings Inc
CEOAdam H. Schechter
Employees71K
Founded1978
HeadquartersBurlington, North Carolina, United States
SectorHealth Care
IndustryHealth care provider
Websitelabcorp.com
Analyst ratings
Based on 14 analysts giving stock ratings to LH in the past 3 months
Strong buy
Buy
11
Hold
3
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for LH in the last 3 months.
Highest
Current $366.57
$420.00 (+14.58%)
Average
$387.18 (+5.62%)
Lowest
$340.00 (-7.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
HSBC
Buy
Upgraded
$410.00
+11.8%
11/05/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$400.00
+9.1%
11/04/2026
David Westenberg
Piper Sandler
Hold
Maintained
$365.00
-0.4%
10/30/2026
David S Macdonald
Truist Financial
Buy
Maintained
$395.00
+7.8%
10/29/2026
Lu Li
Bank of America Securities
Buy
Reiterated
-
-
10/29/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
$355.00
-3.2%
10/29/2026
Kevin Caliendo
UBS
Buy
Reiterated
$420.00
+14.6%
10/29/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
$388.00
+5.8%
10/30/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$396.00
+8%
10/29/2026
Luke Sergott
Barclays
Hold
Maintained
$380.00
+3.7%
10/28/2026
Michael Cherny
Leerink Partners
Buy
Reiterated
$410.00
+11.8%
10/29/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$340.00
-7.2%
09/11/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/11/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
-
-
08/26/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
$360.00
-1.8%
07/30/2026
David Toung
Argus Research
Buy
Maintained
$310.00
-15.4%
06/02/2026
Unknown Analyst
Mizuho Securities
Buy
Reiterated
$320.00
-12.7%
05/27/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
04/30/2026
Last report
Oct 28, 2026
Fiscal period
Q3 2026
$4.78 / $4.64
+2.94%beat
Revenue / Est. (USD)
3.81B / 3.76B
+1.35%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
3.52B
3.54B
3.73B
3.81B
Cost of goods sold
2.52B
2.52B
2.62B
2.70B
Cost of revenue
2.52B
2.52B
2.62B
2.70B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
549.70M
551.00M
577.20M
611.40M
Operating expense
622.30M
626.60M
655.30M
692.60M
Total operating expenses
3.14B
3.15B
3.27B
3.39B
Operating income
370.90M
387.20M
456.70M
415.50M
Other non operating income
1.90M
-600.00K
-3.50M
-5.40M
EBT including unusual items
190.60M
319.70M
386.40M
328.00M
EBT excluding unusual items
315.20M
333.20M
391.50M
341.40M
Income tax expense
25.70M
41.70M
87.30M
64.90M
Effective tax rate
13.48%
13.04%
22.59%
19.79%
Other operating expenses
-
-
-
2.50M
Net income
164.70M
277.80M
298.70M
262.80M
Net profit margin
4.68%
7.85%
8.01%
6.90%
Earnings per share
4.07
4.25
4.99
4.78
Interest and investment income
3.50M
12.20M
5.60M
1.40M
Interest expense
-55.00M
-55.10M
-61.10M
-59.10M
Net interest expenses
-51.50M
-42.90M
-55.50M
-57.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
549.40M
560.50M
635.70M
598.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps